Patents by Inventor Hong-Fen Guo

Hong-Fen Guo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8148154
    Abstract: This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: April 3, 2012
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Nai-Kong V. Cheung, Hong-fen Guo
  • Publication number: 20100226914
    Abstract: This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods.
    Type: Application
    Filed: February 22, 2010
    Publication date: September 9, 2010
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Nai-Kong V. CHEUNG, Hong-fen GUO
  • Patent number: 7666424
    Abstract: This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods.
    Type: Grant
    Filed: October 17, 2002
    Date of Patent: February 23, 2010
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Nai-Kong Cheung, Hong-Fen Guo
  • Publication number: 20030147881
    Abstract: This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods.
    Type: Application
    Filed: October 17, 2002
    Publication date: August 7, 2003
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: Nai-Kong V. Cheung, Hong-Fen Guo
  • Publication number: 20030147808
    Abstract: Recombinant antibody constructs comprise the variable regions of the heavy and light chains of anti-GD2 antibodies. These antibody constructs may be coupled to a label such as a radiolabel or to a protein such as streptavidin or pro-drug converting enzymes for use in imaging or therapeutic applications. The antibody constructs may also be transduced into T cells to produce populations of T cells which target GD2-producing tumor cells.
    Type: Application
    Filed: February 13, 2002
    Publication date: August 7, 2003
    Inventors: Nai-Kong V. Cheung, Steven M. Larson, Hong-Fen Guo, Ken Rivlin, Michel Sadelain
  • Patent number: 6451995
    Abstract: Recombinant antibody constructs comprise the variable regions of the heavy and light chains of anti-GD2 antibodies. These antibody constructs may be coupled to a label such as a radiolabel or to a protein such as streptavidin or pro-drug converting enzymes for use in imaging or therapeutic applications. The antibody constructs may also be transduced into T cells to produce populations of T cells which target GD2-producing tumor cells.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: September 17, 2002
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Nai-Kong V. Cheung, Steven M. Larson, Hong-Fen Guo, Ken Rivlin, Michel Sadelain
  • Publication number: 20020018783
    Abstract: Genetically-modified T cells with enhanced survival in vivo are obtained by transducing T cells with a recombinant polynucleotide encoding a fusion protein comprising a single chain Fv antibody (comprising the variable regions of the heavy and light chains of a selected antibody such as an anti-GD2 antibody) linked to CD28 receptor. T cells expressing this recombinant fusion protein exhibit enhanced survival when reintroduced to an in vivo environment.. These T cells can be used to induce an immune response to cells, particularly tumor cells, when express the antigen for which the antibody is specific. Cells expressing recombinant fusion proteins according to the invention can also be used for in vitro purging of stem cells/bone marrow and for in vivo targeting of tumor cells and other antigen-bearing cells for purposes of imaging.
    Type: Application
    Filed: September 30, 1997
    Publication date: February 14, 2002
    Inventors: MICHEL SADELAIN, NAI-KONG V. CHEUNG, ANJA KRAUSE, HONG-FEN GUO